These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31323113)

  • 21. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
    Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
    Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amisulpride is an "atypical" antipsychotic associated with low weight gain.
    Leucht S; Wagenpfeil S; Hamann J; Kissling W
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):112-5. PubMed ID: 14647963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.
    Garriga M; Fernandez-Egea E; Mallorqui A; Serrano L; Oliveira C; Parellada E; Kirkpatrick B; Vieta E; Bernardo M; Garcia-Rizo C
    J Psychiatr Res; 2019 Aug; 115():29-35. PubMed ID: 31085376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of SNAP25 variants with schizophrenia and antipsychotic-induced weight change in large-scale schizophrenia patients.
    Guan F; Zhang T; Han W; Zhu L; Ni T; Lin H; Liu D; Chen G; Xiao J; Li T
    Schizophr Res; 2020 Jan; 215():250-255. PubMed ID: 31653583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
    Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
    Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight gain and antipsychotics: a drug safety review.
    Musil R; Obermeier M; Russ P; Hamerle M
    Expert Opin Drug Saf; 2015 Jan; 14(1):73-96. PubMed ID: 25400109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis.
    Pollak TA; Vincent A; Iyegbe C; Coutinho E; Jacobson L; Rujescu D; Stone J; Jezequel J; Rogemond V; Jamain S; Groc L; David A; Egerton A; Kahn RS; Honnorat J; Dazzan P; Leboyer M; McGuire P
    Biol Psychiatry; 2021 Jul; 90(1):9-15. PubMed ID: 33536130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
    Papadimitriou GN; Theleritis CG; Dikeos DG; Psarros CJ; Soldatos CR
    Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.
    Zapata RC; Chaudry BS; Valencia ML; Zhang D; Ochsner SA; McKenna NJ; Osborn O
    Transl Psychiatry; 2021 Jul; 11(1):405. PubMed ID: 34294678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain.
    Brandl EJ; Frydrychowicz C; Tiwari AK; Lett TA; Kitzrow W; Büttner S; Ehrlich S; Meltzer HY; Lieberman JA; Kennedy JL; Müller DJ; Puls I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):134-41. PubMed ID: 22426215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial.
    de Boer N; Guloksuz S; van Baal C; Willebrands L; Deenik J; Vinkers CH; Rossum IW; Zinkstok J; Wilting I; Zantvoord JB; Backx F; Swildens WE; Schouw M; Bogers J; Hulshof F; de Knijff R; Duindam P; Veereschild M; Bak M; Frederix G; de Haan L; van Os J; Cahn W; Luykx JJ
    BMC Psychiatry; 2021 Jan; 21(1):4. PubMed ID: 33402159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A2BP1 gene polymorphisms association with olanzapine-induced weight gain.
    Dong L; Yan H; Huang X; Hu X; Yang Y; Ma C; Du B; Lu T; Jin C; Wang L; Yu H; Dong Z; Li W; Ruan Y; Zhang H; Zhang H; Mi W; Ma W; Li K; Lv L; Zhang D; Yue W
    Pharmacol Res; 2015 Sep; 99():155-61. PubMed ID: 26092620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia.
    McIntyre RS; Trakas K; Lin D; Balshaw R; Hwang P; Robinson K; Eggleston A
    Can J Psychiatry; 2003 Nov; 48(10):689-94. PubMed ID: 14674052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses.
    Troudet R; Ali WBH; Bacq-Daian D; Rossum IWV; Boland-Auge A; Battail C; Barau C; ; Rujescu D; McGuire P; Kahn RS; Deleuze JF; Leboyer M; Jamain S
    Neuropsychopharmacology; 2020 Sep; 45(10):1637-1644. PubMed ID: 32450569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of clinical parameters and polygenic risk scores for body mass index, schizophrenia, and diabetes with antipsychotic-induced weight gain.
    Franz M; Papiol S; Simon MS; Barton BB; Glockner C; Spellmann I; Riedel M; Heilbronner U; Zill P; Schulze TG; Musil R
    J Psychiatr Res; 2024 Jan; 169():184-190. PubMed ID: 38042056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.
    Lee K; Abraham S; Cleaver R
    Gen Hosp Psychiatry; 2022; 78():58-67. PubMed ID: 35863294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The positive association between antipsychotic-induced weight gain and therapeutic response: New biotypes of schizophrenia.
    Lu Z; Zhang Y; Sun Y; Liao Y; Kang Z; Feng X; Yan H; Li J; Wang L; Lu T; Zhang D; Huang Y; Yue W
    Psychiatry Res; 2023 Jun; 324():115226. PubMed ID: 37116323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain.
    Brandl EJ; Tiwari AK; Lett TA; Shaikh SA; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
    Hum Psychopharmacol; 2013 Mar; 28(2):183-7. PubMed ID: 23364847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.